Filtered By:
Source: The American Journal of Cardiology
Condition: Diabetes
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 58 results found since Jan 2013.
Sleep Duration and Cardiovascular Health in A Representative Community Population (from NHANES, 2005 to 2016)
We examined the relation between sleep duration and cardiovascular health among the general population in the United States from 2005 to 2016. We sought to investigate associations between sleep duration and the prevalence of coronary artery disease (CAD), heart failure (HF), stroke, hypertension, diabetes mellitus (DM), and hyperlipidemia.
Source: The American Journal of Cardiology - April 25, 2020 Category: Cardiology Authors: Chayakrit Krittanawong, Anirudh Kumar, Zhen Wang, Hani Jneid, Usman Baber, Roxana Mehran, W. H. Wilson Tang, Deepak L. Bhatt Source Type: research
Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF) and stroke being the main contributors.1 Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), along with the ...
Source: The American Journal of Cardiology - August 6, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas Source Type: research
Comparison of Frequency of Atrial Fibrillation in Blacks versus Whites and the Utilization of Race in a Novel Risk Score
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia in the world, with over 30 million people affected as of 2010.1 The number of patients projected to develop AF will double over the next decade.2 AF is independently associated with an increased risk of stroke,3 heart failure (HF),4 and mortality.5 It is not surprising, thus, that AF assumes a sizeable share of health care expenditure and its magnitude is reaching epidemic proportions.6 Blacks despite having a higher prevalence of traditional risk factors for AF, such as HF, hypertension, and diabetes mellitus, have been shown to have a lower incidence of AF.
Source: The American Journal of Cardiology - August 27, 2020 Category: Cardiology Authors: Gurukripa N. Kowlgi, Sampath Gunda, Santosh K. Padala, Jayanthi N. Koneru, Abhishek J. Deshmukh, Kenneth A. Ellenbogen Source Type: research
Cardiovascular Risk Among Patients ≥ 65 Years of Age with Parkinson's Disease (From the National Inpatient Sample)
In this study, we aimed to investigate the relationship between PD and vascular disease and risk factors using a nationally representative sample. The National Inpatient Sample (NIS) was queried for all patients aged ≥ 65 who were diagnosed with PD during the year 2016. Patients were identified using the International Classification of Diseases—Tenth Revision (ICD-10) diagnosis code: "G20". Each patient diagnosed with PD was frequency-matched to controls at a 1:4 ratio by age and gender. Study outcomes were hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease and stroke.
Source: The American Journal of Cardiology - September 13, 2020 Category: Cardiology Authors: Ashraf Abugroun, Ahmed Taha, Manar Abdel-Rahman, Pragnesh Patel, Ibtisam Ali, Lloyd W Klein Source Type: research
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) after Percutaneous Coronary Intervention in High-Risk Patients with Diabetes Mellitus
The efficacy and safety of prolonged (>1-year) dual antiplatelet therapy (DAPT) duration in high-risk patients with diabetes mellitus (DM) undergoing PCI remain unknown. All patients undergoing PCI at Fuwai hospital between January 2013 and December 2013 were prospectively enrolled into the Fuwai PCI registry. 3696 high-risk diabetics patients with at least one additional atherothrombotic risk factor were screened for inclusion. The primary efficacy outcome was the composite of all-cause mortality, myocardial infarction, or stroke.
Source: The American Journal of Cardiology - December 4, 2020 Category: Cardiology Authors: Hao-Yu Wang, Zhong-Xing Cai, Dong Yin, Yue-Jin Yang, Wei-Hua Song, Ke-Fei Dou Source Type: research
Triglyceride –Rich Lipoproteins, Apolipoproteins, and Atherosclerotic Cardiovascular Events Among Patients with Diabetes Mellitus and End–Stage Renal Disease on Hemodialysis
Hypertriglyceridemia may be implicated in the high atherosclerotic cardiovascular disease (ASCVD) risk experienced by patients with end –stage renal disease (ESRD). In this post–hoc analysis of the “Die Deutsche Diabetes Dialyse Studie (4D)” clinical trial, we examined incident ASCVD events, defined as myocardial infarction, ischemic stroke, or a coronary revascularization procedure, among 1255 participants with type 2 diabe tes and ESRD treated with hemodialysis. Cox–regression methods were used to evaluate the association of triglycerides, very–low density lipoprotein cholesterol (VLDL–C), and apolipoprotei...
Source: The American Journal of Cardiology - June 6, 2021 Category: Cardiology Authors: Julio A. Lamprea –Montealegre, Ronit Katz, Hubert Scharnagl, Günther Silbernagel, Winfried März, Christiane Drechsler, Cristoph Wanner, Ian H. de Boer Source Type: research
Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus
The objective of this study was to analyze randomized controlled trials (RCT) testing GLP-1 RA's effect on CVD events among participants with type 2 diabetes (T2DM). RCTs comparing GLP-1 RA versus placebo were identified using the PubMed and Cochrane databases. The endpoints in this study included major adverse cardiovascular events (MACE; a composite of cardiovascular death, nonfatal myocardial infarction (MI), and nonfatal stroke), and the individual components of MACE.
Source: The American Journal of Cardiology - July 12, 2021 Category: Cardiology Authors: Simran Grewal, Ninad Zaman, Louis Borgatta, Matthew Nudy, Andrew J. Foy, Brandon Peterson Source Type: research
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Atrial fibrillation (AF) constitutes the most common, major cardiac arrhythmia worldwide, with an estimated prevalence in the United States equal to 2.3 million affected subjects, projected to increase to 5.6 million by 2050.1 Hypertension and background heart disease (mainly, congestive heart failure) or valve disease represent main risk factors for AF development.1 Other modifiable risk factors are sedentary lifestyle, smoking, obesity, diabetes mellitus, and obstructive sleep apnea.2 AF is associated with a significant increase in the risk for all-cause and cardiovascular death, ischemic stroke, heart failure (HF), isch...
Source: The American Journal of Cardiology - August 13, 2021 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, Michael Doumas Source Type: research
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, myocardial infarction, or ischemic stroke and hospitalization for heart failure in patients with T2DM and atrial fibrillation (AF). Using the Korean National Health Insurance Service database, we identified 40,268 patients with T2DM and AF who were newly prescribed oral hypoglycemic drugs ...
Source: The American Journal of Cardiology - July 7, 2022 Category: Cardiology Authors: Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim Source Type: research
CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation
Patients with atrial fibrillation (AF) are at increased cardiovascular risk. The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, female gender) has been used to predict thromboembolic risk in patients with nonvalvular AF. We aimed to evaluate the association between the CHA2DS2-VASc score and the risk of acute myocardial infarction (AMI) a nd all-cause mortality in patients with AF treated with direct oral anticoagulants (DOACs).
Source: The American Journal of Cardiology - August 12, 2022 Category: Cardiology Authors: Mustafa Gabarin, Tzipi Hornik-Lurie, Saar Minha, Alexander Omelchenko, Rami Barashi, Ziad Arow, Abid Assali, David Pereg Source Type: research
Usefulness of Self-Reported Physical Activity and Clinical Outcomes in Older Patients With Atrial Fibrillation
Current guidelines encourage regular physical activity (PA) to gain cardiovascular health benefit. However, little is known about whether older adults with atrial fibrillation (AF) who engage in the guideline-recommended level of PA are less likely to experience clinically relevant outcomes. We did a retrospective study based on the data from Systemic Assessment of Geriatric Elements in AF (SAGE-AF) prospective cohort study. The study population consisted of older participants with AF ( ≥65 years) and a congestive heart failure, hypertension, age, diabetes, stroke vascular disease, age 65 to 75 and sex(CHA2DS2-VASc) score ≥2.
Source: The American Journal of Cardiology - August 16, 2022 Category: Cardiology Authors: Qiying Dai, Jordy Mehawej, Jane S. Saczynski, Khanh-Van Tran, Hawa O. Abu, Darleen Lessard, Andreas Fillippaios, Tenes Paul, Essa Hariri, Weijia Wang, Mayra Tisminetzky, Apurv Soni, Sakeina Howard-Wilson, Molly E. Waring, Robert J. Goldberg, David D. McMa Source Type: research
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research
Percutaneous Left Atrial Appendage Closure Among Patients With Diabetes (Insights from a National Database)
Atrial fibrillation is a major risk factor for stroke. Left atrial appendage closure (LAAC) has emerged as an alternative to anticoagulation for patients with high risk of bleeding. Diabetes mellitus (DM) is associated with adverse events after cardiac procedures. We sought to compare procedural and hospital outcomes in patients who underwent LAAC with and without DM. The Nationwide Inpatient Database was queried for patients with atrial fibrillation who underwent LAAC between January 1, 2016, and December 31, 2019.
Source: The American Journal of Cardiology - July 11, 2023 Category: Cardiology Authors: Mohamed Hamed, Ramez Morcos, Ayman Elbadawi, Ahmed Osman, Hani Jneid, Wissam Khalife, Brijeshwar Maini, Houman Khalili Source Type: research
